Cytokinetics Inc. vs Abbvie Inc.
CYTK vs ABBV — side-by-side comparison from reported financials. CYTK leads 1, ABBV leads 7 of 8 comparable metrics.
Cytokinetics Inc.
CYTK · Healthcare
$62.91+1.45%Strained
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
| Metric | CYTK | ABBV |
|---|---|---|
| Price | $62.91 | $276.43 |
| Market cap | $8.75B | $488B |
| Revenue (TTM) | $67.7M | $64.4B |
| Revenue growth | -2.4% | +1.8% |
| Net margin | -1321.3% | 9.8% |
| Free cash flow | -$581M | $18.2B |
| Net cash (debt) | $636M | ($56.2B) |
| 1-year price return | +4.3% | +19.8% |
| P/E | — | 77.4 |
| P/E vs own history (cheap-side %) | — | 23% |
| Dividend yield | — | 2.45% |
| Return on equity | -131% | 96% |
| Altman Z-score | — | 2.33 |
| CV checks passed | 3 of 9 | 9 of 9 |
| Employees | 673 | 57,000 |
Full résumé-style profiles: CYTK CV · ABBV CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.